Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Grail Inc.

grail.com

Latest From Grail Inc.

Deal Watch: GSK Furthers Cancer Gene Therapy Plans Via Lyell Collaboration

GSK hopes the San Francisco biotech’s technology can help its cell therapy pipeline address solid tumors. Avacta partners with ADC on antibody-drug conjugates.

Deals Business Strategies

Carrick Targets Ovarian Cancer With BTG Deal, Entices Celgene’s Former Top Deal Maker

In a busy week, Carrick Therapeutics has added to its oncology pipeline, as well as bringing in Celgene deal maker George Golumbeski.

Deals Cancer

Appointments: Senior Hires At Allergan, Novartis, Array Biopharma, Zelluna Immunotherapy, Grail, Alzheon And Sigilon Therapeutics

Pfizer Oncology has lost its CMO to Allergan, while Novartis beefs up its ethical leadership, Array Biopharma appoints a new chair and Sigilon raids Bioverativ for its new CEO.

Appointments Commercial

Market Intel: Liquid Biopsy I – Analyzing Market Landmarks And Landmines

The worldwide liquid biopsy market is expected to reach $2.0bn by 2022, according to a new report by Meddevicetracker, "Oncology: Liquid Biopsy Products." The growth is driven by the rising global incidence of cancers, which, in turn, fuels innovation among companies to develop noninvasive diagnostic assays that obviate the need for tissue biopsy. This is the first in a two-part series providing an overview of the liquid biopsy market, as well as the technologies developed by the larger players in this space, and examining the biggest barriers and growth drivers. In the second part, we'll take a closer look at emerging companies in the sector and offer key insights from C-level attendees at the recent Liquid Biopsy Conference in San Francisco.

Cancer In Vitro Diagnostics
See All

Company Information

  • Industry
  • Biotechnology
  • In Vitro Diagnostics
    • Molecular Diagnostics & Genetic Testing
  • Therapeutic Areas
  • Cancer
  • Alias(es)
  • Grail Bio
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Company Type
  • Start-Up
  • Parent & Subsidiaries
  • Grail Inc.
  • Senior Management
  • Hans Bishop, CEO
    Matthew Young, COO & CFO
    George Golumbeski, PhD, Pres.
    Alex Aravanis, MD, PhD, CSO
    Onaisz Cadoret-Manier, Chief Commercial Officer
    Angela Lai, CTO
  • Contact Info
  • Grail Inc.
    Phone: (650) 542-0372
    1525 O'Brien Dr.
    Menlo Park, CA 94025
    USA
UsernamePublicRestriction

Register